---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093945"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:46:28.749888+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology Q2 net loss $50.8M; cash $491.5M; ziftomenib pivotal data expected early 2025

## Summary
- Net loss $50.8M in Q2 2024 vs $37.2M in Q2 2023; R&D expenses $39.7M vs $28.2M.
- Cash, equivalents & short-term investments $491.5M at June 30, 2024; runway into 2027.
- Ziftomenib completed enrollment of 85 patients in KOMET-001 pivotal trial; FDA Breakthrough Therapy Designation; topline data early 2025.
- Phase 1b expansion of KOMET-007 (ziftomenib + ven/aza and 7+3) now enrolling; data expected Q4 2024.
- IND cleared for ziftomenib in GIST; proof-of-concept study with imatinib planned H1 2025.

## SEC filing metadata
- accession: 0000950170-24-093945
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000095017024093945/0000950170-24-093945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000095017024093945/kura-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093945
- JSON: https://secwatch.observer/filing/0000950170-24-093945.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093945.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.